Physician profile
Christopher D Codispoti
NPI 1922219211
$2,511.66
in general payments reported to CMS, 2019-2025
18 companies · $1,767 in 2025
The $1,767 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.20 · 2022: $120 · 2023: $109 · 2024: $498 · 2025: $1,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.79 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $686.27 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Blueprint Medicines Corporation | $560.33 | 2023-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $222.35 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $189.73 | 2025 | |
| Genzyme Corporation | $184.48 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.94 | 2024-2025 | Cuvitru |
| Alk-Abello, INC | $119.90 | 2022 | |
| Pharming Healthcare, INC. | $73.21 | 2024-2025 | Ruconest |
| Csl Behring | $72.45 | 2025 | Hizentra |
| Glaxosmithkline, LLC. | $43.23 | 2025 | Nucala |
| Grifols USA, LLC | $36.21 | 2024-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $29.79 | 2025 | Neffy |
| Lilly USA, LLC | $24.46 | 2025 | Ebglyss |
| Paratek Pharmaceuticals, INC. | $20.83 | 2025 | Xhance |
| Cycle Pharmaceuticals INC | $20.70 | 2025 | Sajazir |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $17.20 | 2020 | |
| Phadia US INC. | $15.25 | 2025 | Immunocap |
| Gc Biopharma USA, INC. | $13.33 | 2024 | Alyglo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Codispoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.